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Summary The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (slL-2R) in Hodgkin's disease (HD) both
in the achievement of complete remission (CR) and in predicting disease relapse. Between August 1988 and June 1993 slL-2R serum levels
were measured in 174 untreated patients; in 137 of them evaluation was repeated at the end of treatment and in 132 also during the follow-
up. Baseline slL-2R levels (mean ± standard error) were significantly higher in patients than in 65 healthy control subjects (1842 ± 129 U ml-1
vs 420 ± 10 U mI-', P< 0.0001). At the end of treatment 135 out of 137 evaluated patients achieved complete response (CR) and their mean
slL-2R serum levels were significantly lower than those at diagnosis (635 ± 19 U mi-' vs 1795 ± 122 U ml-, P= 0.0001). After a median
follow-up of 5 years, slL-2R remained low in 114 patients in continuous CR, while they increased in 9 out of 12 patients (75%) who relapsed.
However, a temporary increase was also observed in six patients (5%) still in CR. Treatment outcome in terms of freedom from progression
was linearly related to slL-2R levels. Our study confirms that patients with untreated HD have increased baseline levels of slL-2R compared
with healthy subjects and that their pretreatment values may be an indication of disease outcome similar to other conventional prognostic
factors, such as number of involved sites, presence of B symptoms and extranodal extent.
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In the last two decades, great progress has been achieved in the
cure ofHodgkin's disease. Nevertheless, about 30% ofpatients are
still refractory to initial treatment and are candidates for alternative
approaches (Santoro and Valagussa, 1992). Several patient charac-
teristics and clinical features have been correlated with disease
outcome, in an attempt to identify the group ofpatients athigh risk
oflymphoma progression who mightbenefit from more intensified
treatment approaches at the time of initial diagnosis, as well as
those who can be managed with less intensive therapy to minimize
iatrogenic sequelae.
From the clinical point of view, the prognostic factors most
widely evaluated are related to tumour burden, including stage,
number of involved sites, extranodal extent, bulky disease, extent
of splenic involvement, systemic symptoms and pulmonary hilus
involvement. In multivariate analyses, however, no single factor
proved to offer independent prognostic information (Specht et al,
1988; Straus et al, 1990; Proctor et al, 1992). In contrast, only a
few studies have been carried out to establish the prognostic
significance ofhost immune status-related factors.
Recently, the prognostic value ofvarious immunological factors
has been investigated, based on the evidence of the well-known
defect in cell-mediated immunological reactions in patients with
Hodgkin's disease, in particular with advanced stage and/or in the
presence of systemic symptoms (Romagnani et al, 1985; Gause et
al, 1992a; Clerici et al, 1994). Several cytokines and soluble forms
of cell-surface antigens of lymphocytes and Reed-Steinberg (RS)
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cells or reactive cells found in tissues involved by Hodgkin's
disease, such as CD30, CD8 and CD25 have been evaluated.
(Rubin et al, 1985; Hsu and Hsu, 1990; Kretschmer et al, 1990;
Pfreundschuh et al, 1990; Grimfors et al, 1991; Gause et al,
1992b). Recent clinical studies suggest a prognostic value of the
soluble form ofinterleukin-2 receptor (IL-2R) (Pizzolo et al, 1987;
Pui et al, 1989b; Gause et al, 1991, 1992a; Enblad et al, 1995). IL-
2R is expressed on the Hodgkin's disease and RS cells; moreover
the malignant cells and Hodgkin's disease-RS-derived cell lines,
when cultured in vitro, release to the supernatant a soluble form,
the so-called soluble interleukin-2 receptor (sIL-2R) (Rubin and
Nelson, 1990). It consists of the p55 fragment of the whole IL-2
cell-surface receptor. The sIL-2R proved to be also released into
the blood. Even though its affinity for circulating IL-2 is lower
than that for the whole cell-surface receptor, sIL-2R has retained
its ability to bind circulating IL-2 (Rubin et al, 1986). Soluble IL-
2R can determine a diminished IL-2 biological availability and can
consequently be involved in the impaired T-cell function described
in Hodgkin's disease patients (Gooding et al, 1995). This compro-
mised host's anti-tumour immunity could lead to unusually
aggressive disease. In fact, abnormally high blood levels ofsIL-2R
have been detected in several clinical states characterized by
suppression of cellular immunity, including AIDS and metastatic
solid tumours (Kloster et al, 1987; Rovelli et al, 1988). Moreover,
recent clinical studies have also pointed out that elevated sIL-2R
levels play a negative prognostic role in various malignancies,
such as metastatic solid tumours, hairy cell leukaemia, chronic
leukaemia, acute lymphoblastic leukaemia and lymphomas
(Pizzolo et al, 1987; Semenzato et al, 1987; Pui et al, 1988a, 1989;
Rovelli et al, 1988; Steis et al, 1988; Chilosi et al, 1989; Motoi et
al, 1989; Gause et al, 1992a; Enblad et al, 1995).
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The aim of this study was to evaluate the correlation of sIL-2R
levels in Hodgkin's disease patients with established factors
known to influence clinical outcome, namely stage, B-symptoms,
number of involved sites, bulky disease and extranodal extent. In
addition, we investigated the prognostic role of sIL-2R and
whether its levels measured after treatment and during follow-up
could be used as a serum marker that is readily accessible, objec-
tive and easily evaluable to predict lymphoma reappearance.
PATIENTS AND METHODS
Patients
From August 1988 to June 1993, sIL-2R were evaluated before the
start of treatment in 174 untreated patients with histologically
proven Hodgkin's disease enrolled in different prospective clinical
trials. The main patient characteristics are reported in Table 1.
Median age was 28 years (range 16-69 years) and nodular
sclerosis represented the single most frequent histological subset,
accounting for 76% of the entire case series. About half of the
patients presented with systemic symptoms and/or with more than
three involved sites, and one-quarter of the patients had bulky
disease.
Patients were staged according to the Ann Arbor classification
reviewed at Costwold (Lister et al, 1989). Staging procedures
included complete physical examination, haemogram with differ-
ential, liver and renal function tests, erythrocyte sedimentation
rate, serum copper level, posteroanterior and lateral chest
roentgenograms, bipedal lymphangiography, two needle bone
marrow core biopsies from bilateral posterior iliac crest and
thoracic and abdominal computerized tomographic scan.
Additional radiographs as well as radioisotopic studies were
performed only in the presence of given clinical situations. The
abdominal extent ofdisease was evaluated through staging laparo-
tomy, including splenectomy in 11 patients.
Treatment
All patients received stage-directed therapy. Treatment modalities
and their median duration, as well as main therapeutic results, are
listed in Table 2. Patients in PS IA were treated with subtotal nodal
radiotherapy (STNI); until June 1990 patients in PS IIA were also
treated with STNI; from July 1990 patients in PS IB and IIA were
given four cycles ofABVD (doxorubicin, bleomycin, vinblastine,
dacarbazine) followed by involved-field or subtotal nodal radio-
therapy (RT). Patients with PS IIB, III and IV were treated with
MOPP (mechlorethamine, vincristine, procarbazine and pred-
nisone) alternated with ABVD for eight cycles followed by RT
on the bulky site(s) of disease. From July 1990, these patient
subgroups were given eight cycles of VEBEP (etoposide,
epidoxorubicin, bleomycin, cyclophosphamide and prednisone)
followed by involved-field RT at a median dose of30 Gy.
Soluble IL-2 receptors
To evaluate serum levels of sIL-2R, venous blood samples were
drawn from 174 patients immediately before the start oftreatment,
from 137 patients within 1 month after completion oftherapy and
from 132 patients during follow-up at different time intervals. The
sera were stored in-20°C, coded and tested blindly. Serum sIL-2R
were determined by the commercially available sandwich Elisa
Table 1 Patient characteristics
No. %
Total 174 100
Men 90 52
Women 84 48
Age (years)
.40 143 82
>40 31 18
Histology
Nodular sclerosis 132 76
Others 42 24
B symptoms
No 95 55
Yes 79 45
Nodal involvement 140 80
Extra ± nodal involvement 34 20
< Three involved sites 102 59
> Three involved sites 72 41
Bulky disease
No 131 75
Yes 43 25
STAGE
1 27 15
11 101 58
III 32 18
IV 14 9
test kit (T-cell Sciences, Cambridge, MA, USA). Samples were
assayed in duplicate. The sera of 65 healthy subjects with similar
median and age range served as controls.
Statistical methods
Differences in the mean values of sIL-2R in the various patient
subgroups were calculated using the t-test. When follow-up sera
were assessed, the t-testforpaired values was used. Freedom from
progression (FFP) was calculated from the date of starting treat-
ment to the first evidence of disease progression. The pattern
of FFP was estimated by means of the product-limit method
(Kaplan-Meier) (Kaplan and Meier, 1958).
Therole ofpotentially significant prognostic factors on FFP was
investigated in univariate analysis using a Cox regression model
(Cox, 1972). In this model, each regression coefficient (0) is the
logarithm of the hazard ratio (HR), which is assumed constant in
time. Under the null hypothesis that a variable has no prognostic
role on FFP, HR is expected to be 1.00. The hypothesis of HR =
1.00 was tested using the Wald statistic. The sIL-2R serum level
was analysed as continuous variable. The relationship between
sIL-2R levels and FFP was investigated by resorting to a regres-
sion model based on restricted cubic splines. The most complex
model considered was a four-nodes cubic spline with nodes
located at the quartiles of the distribution of the sIL-2R
(Durrleman and Simon, 1989). The contribution of non-linear
terms was evaluated by the likelihood ratio test. As sIL-2R was
used as continuous variable, the values of HR concerning the
unitary increment were not adequately informative. Therefore, we
present the results related to an increment of 1000 U m1'. In order
to allow the reader to calculate HR for each sIL-2R increase, we
provide the regression coefficient estimates (0) from which it is
possible to obtain HR value for each sIL-2R increase.
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Table 2 Therapeutic results according to treatment subgroups
Treatment No. of patients CR 5-year FFP
(median duration (%) (%)
in months) Stage Stage
1-11 IlM-V
RT(2) 23 0 100 83
ABVD+RT (6) 58 0 98 96
MOPP/ABVD (9) 24 24 92 81
VEBEP+RT (8) 23 22 96 74
CR, complete remission; FFP, freedom from progression.
RESULTS
Pretreatment sera
The mean sIL-2R level in patients with newly diagnosed untreated
Hodgkin's disease was 1842 U ml-' and ranged from 321 to
10 770 U ml-', while in normal controls they were significantly
lower ranging from 295 to 760 U ml-', with a mean value of
420 U ml-' (P < 0.0001).
The relation between main patient characteristics and sIL-2R
levels is reported in Table 3. Patients with B symptoms, more than
three involved sites and advanced stage (stages III and IV) had
significantly higher levels than their counterparts. Also, the small
fraction of patients with extranodal extent had mean levels supe-
rior to those detected in patients presenting with nodal involve-
ment alone. No significant relations were found when gender, age
groups and histopathological subgroups were considered.
As illustrated in Figure 1, a linearrelationship between the loga-
rithm ofhazard and sIL-2R serum values was detected. Univariate
analyses showed that sIL-2R levels were unable to significantly
influence (at conventional 5% level) the 5-year FFP ( = 0.000153,
HR = 1.16, 95% confidence interval 1.15-1.18, P 0.067). The
most important factors able to influence FFP were the presence of
systemic symptoms (presence vs absence of systemic symptoms:
HR = 2.34, 95% confidence interval 1.04-5.25, P = 0.039) and the
extent of disease expressed by number of involved sites (> vs <
three involved sites: HR = 2.37, 95% confidence interval
1.07-5.22, P 0.032).
Post-therapy sera
Soluble IL-2 receptors were also evaluated in 137 out of 174 patients
immediately after the end of the entire treatment plan; 135 patients
achieved complete remission (CR), one patient achieved only a
partial remission (PR) and one showed lymphoma progression. The
mean values ofpatients achieving CR were significantly lower than
those observed at diagnosis (635 ± 19 vs 1795 ± 122, P = 0.0001).
However, values within the normal range, i.e. < 500 U ml-', were
observed in only 41 out of 135 (30%) patients achieving CR.
Follow-up sera
Soluble IL-2R serum levels were determined at least once in 132 out
of the 135 patients who were in CR at the end of treatment. They
remained low in the 114 patients who were in continuous CR
(429.5±40.4) after a median of 56 months from the end ofall thera-
pies, while an increase was observed in 9 out of 12 (75%) patients
who showed disease relapse after a median of 16 months (range
Table 3 Mean serum slL-2R levels according to patient characteristics
slL-2R (U ml-' P
(mean ± s.e.a)
Total 1842 ± 129
Men 1909±198
Women 1770± 163 0.59
Age (years)
< 40 1911 ± 151
> 40 1521 ± 194 0.12
Hystology
NS 1628± 110
Others 2514± 394 0.035
B symptoms
No 1279 ±96
Yes 2518± 239 0.0001
Nodal 1655± 110
Extra ± nodal 2607+ 461 0.0053
< Three involved sites 1220 ± 80
> Three involved sites 2722 ± 257 0.0001
Bulky
No 1704 ± 155
Yes 2261 ±215 0.0622
Stage
l-ll 1362 ± 76
III-IV 3176± 377 0.0001
aStandard error. P-value (at the conventional significance of 5% level) related
to performed t-test.
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Figure 1 Five-year freedom from progression according to slL-2R serum
levels
5-31 months) fromthe end oftreatment. As illustrated in Table 4, in
the 12 patients who relapsed, the values measured at the end of
therapy were reduced compared with basal values in all but one
patient who experienced an early relapse 5 months later. The table
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Table 4 Outcome of slL-2R levels in 12 relapsing patients
slL-2R (U ml-1)
Case At diagnosis At end of At last At relapse
therapy follow-up (months) (months)
1 1365 630 515 (2) 750a (5)
2 1395 1202 NA 3560a (5)
3 1410 435 400 (4) 250 (7)
4 463 332 NA 511 (7)
5 1400 510 400 (6) 71Oa (10)
6 1381 817 1165b (5) 1360a (10)
7 1286 569 314 (3) 500 (13)
8 3793 570 405 (4) 2800a (16)
9 1212 712 3900b (19) 6500a (22)
10 4290 428 703b (15) 819a (22)
11 2412 490 9oob (22) 1070a (26)
12 1530 680 978b (24) 9gOa (31)
aPatients with increase of slL-2R levels at relapse. bPatients with increase of slL-2R levels at the follow-up visit preceding the
clinical evidence of relapse. (), Time of slL-2R levels measurement during follow-up and time of clinical evidence of relapse,
both calculated in months from the end of all therapies. NA, not assessed.
Table 5 Mean serum slL-2R levels in 135 patients according to disease
status
slL-2R P
(mean ± SE)
Before therapy
Continuous CR 1722 ±463 0.07
Relapse 1896 ± 150
After therapy
Continuous CR 627± 62 NS
Relapse 636 ± 20
also reports the sIL-2R values from samples obtained during the
follow-up visit preceding the clinical documentation of lymphoma
relapse. It is important to note that in five out ofthe nine cases with
high sIL-2R values at relapse, these levels were already increased
some months (median 7, range 4-15) before clinical evidence of
recurrent disease. Nevertheless, considering the entire case series,
the group of41 cases, who at achievementofCRhadnormal sLL-2R
values, had a similar disease recurrence rate (10%) compared with
the group of 94 patients with sIL-2R levels above normal range at
CR (8.5%). When the mean values ofsIL-2R, measured before and
at the end oftherapy in patients who relapsed, were compared with
those measured inpatients whoremainedin CR, no difference could
be detected, as reported in Table 5. A temporary increase of sIL-2R
was observed in six patients who are still in continuous CR. This
increase was due to intercurrent infections in two cases, radiation
pneumonitis in one case, hyperplastic adenopathies in one case and
undetermined reasons in the remaining two patients. The median
degree ofincreased levels with respect to the values observed at the
previous control was of 105.5% (range 21-239%), and the median
time from observation of sIL-2R increase to last follow-up was 67
months (range 44-78 months).
DISCUSSION
The findings of our study are in line with data reported by other
investigators (Pizzolo et al, 1987; Pui et al, 1989a; Gause et al,
1991, 1992a and b; Enblad et al, 1995; Gorschluter et al, 1995). In
fact they confirm that patients with untreated Hodgkin's disease
have increased baseline levels of sIL-2R compared with healthy
subjects and that their pretreatment values correlate with the
conventional unfavourable indicators in Hodgkin's lymphoma,
such as advanced stage, bulky disease, number of involved sites
and the presence of systemic symptoms. We were unable to
observe an influence of sIL-2R values on the achievement ofCR,
and this was probably due to the very high CR rate obtained with
the different treatments tailored to the stage of the disease.
Nevertheless, as also observed by other authors, treatment
outcome in terms of freedom from progression suggested that
patients with normal orlow sIL-2R pretreatment levels may have a
more favourable prognosis, the 5-year FFP being, in our case
series, 93% in 56 patients with sIL-2R levels < 1000 U ml-' and
80% in the 118 patients with levels 2 1000 U ml-.
Our observation of the outcome of sIL-2R levels at diagnosis
and during follow-up in relapsing patients indicates that the
relative values in individual cases, rather than the absolute values,
have clinical relevance. Evaluating the possible usefulness of
monitoring sIL-2R levels for therapeutic decisions, we need to
considerthat not all patients suffering fromrelapse had an increase
ofsIL-2R values, and that a rise during follow-up was sporadically
documented also in non-neoplastic conditions influenced by
unspecific intercurrent events that stimulate the immune system.
Therefore, the impact of this variable as definitive indicator in
treatment decision-making remains uncertain.
Besides sIL-2R, a number ofantigens and cytokines involved in
the biology of Hodgkin's disease and the immune response have
recently been investigated in serum samples of patients with
Hodgkin's lymphoma (Pui et al, 1989b; Grimfors et al, 1991;
Gause et al, 1992b; Kurzrock et al, 1993; Blay et al, 1994;
Triimper et al, 1994; Gorschluter et al, 1995). In particular
increased sCD8 and sCD30 have been demonstrated to be associ-
ated with a poor prognosis, even though only sCD30 seem to be
strictly correlated with disease activity (Pui et al, 1989b; Grimfors
et al, 1991; Gause et al, 1992a). In addition, significant correla-
tions were reported either between sCD30 and sIL-2R levels or
between sCD8 and sIL-2R serum levels (Gause et al, 1992a).
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As far as interleukin levels are concerned, abnormally high
blood concentrations of IL-6, IL-7 and IL-8 have been generally
described in Hodgkin's disease, whereas IL-1, IL-2, IL-3 and IL-4
are rarely detectable (Gause et al, 1992b; Kurzrock et al, 1993;
Blay et al, 1994; Trumper et al, 1994; Gorschluiter et al, 1995).
In order to confirm previous results and to better understand
the cytokine network involved in immunodeficiency related to
Hodgkin's disease, we continue to evaluate in our case series sIL-
2R, and we have also planned to simultaneously detect IL-2 and
IL-I2, the two main anti-tumour cytokines in humans, as well as
IL-6 and IL-1O, which play an important role in inducing immuno-
suppression (Wanebo et al, 1986; Matsuda and Hirano, 1990;
Howard and O'Garra, 1992; Banks et al, 1995).
In conclusion, the results of the present study confirm that
sIL-2R values correlate with disease spread and represent a
host immune status-related factor associated with disease
outcome, as with other conventional clinical prognostic factors.
Therefore, their inclusion in the clinical evaluation should be
taken into consideration, with the aim to have an additional
guide for treatment decisions at initial diagnosis or during the
follow-up.
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